Business
Bioventus Reports First Quarter Financial Results
Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15 per diluted share compared to $0.08 per diluted share in the prior-year periodCash from operations of $8.9 million increased $28.3 million compared to the $19.3 million cash outflow in the prior-year periodCompany raises Non-GAAP EPS* and Cash from Operations guidance and reaffirms revenue guidance fo
About this update from Biovie Inc.
[{"type":"image","alt":"Bioventus, Inc.","displaySize":"","headline":null,"caption":"Bioventus, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/17b9c15cccb55f628dbafce6298a0302"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9JE6Yi5DjA2tD.SI5Pw_Yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3/https://media.zenfs.com/en/globenewswire.com/17b9c15cccb55f628dbafce6298a0302","width":300,"height":55}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Q1 reported revenue of $132.1 million increased 7%","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-GAAP earnings* of $0.15 per diluted share compared to $0.08 per diluted share in the prior-year period","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash from operations of $8.9 million increased $28.3 million compared to the $19.3 million cash outflow in the prior-year period","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Company raises Non-GAAP EPS* and Cash from Operations guidance and reaffirms revenue guidance for full year 2026","length":112,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":516,"olType":false},{"type":"text","content":"DURHAM, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 28, 2026.","length":254,"tagName":"p"},{"type":"text","content":"“Our team delivered a strong start to 2026, driven by continued momentum in our core businesses and disciplined execution across our commercial and operational priorities,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “We are focused on delivering above market growth for the year, while maintaining peer-leading gross margins, which allows us to reinvest in our multiple growth drivers, expand profitability, and generate strong cash flow, positioning Bioventus to deliver sustainable long-term shareholder value.”","length":539,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Fina...